Ascent Scientific Launches mGlu7 agonist – the First of Its Kind - To Help Research Into Anxiety Disorders

Ascent Scientific (www.ascentscientific.com) announced the addition of a ground-breaking new research tool to the Low-Cost Ligand range – a tool that will aid research into anxiety and stress-related disorders.

(PRWEB) October 13, 2005 -- Ascent Scientific (www.ascentscientific.com) announced the addition of a ground-breaking new research tool to the Low-Cost Ligand range – a tool that will aid research into anxiety and stress-related disorders. The research tool is a chemical called AMN082, and it selectively activates a particular protein in the brain - the mGlu7 glutamate receptor subtype. These receptors are thought to be involved in anxiety and stress-related disorders.

Steve Roome PhD, Commercial Director commented, “We are delighted to be the first life science supplier to make this exciting research tool commercially available to the scientific community. Since the disclosure of this chemical at the recent 5th International mGlu meeting in Taormina last month, our chemists have been working tirelessly to make it available as quickly as possible.”

Iain Sandison, Science Director “The addition of AMN082 to the Low-Cost Ligand range promises to be valuable asset for scientists researching anxiety and stress-related disorders. We have made it available at a very high purity, and of course, in keeping with our philosophy to make research tools affordable for as many researchers as possible – at a very low price.”

About Ascent Scientific

Ascent Scientific provides high quality receptor ligands, synthetic chemistry, research, consultancy and analytical services for life science, pharmaceutical and chemistry-related industries.

The Low-Cost Ligand range includes:

- AMN082: the first selective mGlu7 agonist

- L-AP4: selective group III mGlu agonist

- (S)-3,4 DCPG: Potent selective mGlu8a agonist

- (S)-3,5-DHPG: Selective group 1 mGlu agonist

- MPEP: mGlu5 selective antagonist

- D-AP5: Potent selective NMDA antagonist

- Quisqualic acid: glutamate agonist

- PPADS: purinergic agonist

Contact:

Steve Roome,

Commercial Director

+44 (0)1934 624 695

###